Clinical Trial Update: A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of REGN2810 (cemiplimab) in combination with ipilimumab for advanced non-small cell lung carcinoma has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• REGN2810
• ipilimumab (ipilimumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Advanced Non-Small Cell Lung Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-11-03